Kiora Pharmaceuticals

About:

Kiora Pharmaceuticals develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system.

Website: https://kiorapharma.com

Twitter/X: KioraPharma

Top Investors: Ventech, Nantahala Capital Management, Generis Capital Partners, Armistice Capital, Stonepine Capital Management

Description:

Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.